Washington, DC 20006-5349
HELPLINE
This week, the Meso Foundation is happy to welcome two new members of our Washington, D.C. office staff: Michael Braeuninger and Jordan Fingerhut. Michael joins…
The Mesothelioma Applied Research Foundation (Meso Foundation) is excited to announce this week the addition of five new members to the Board of Directors: Richard…
A Russian asbestos company is now flippantly marketing its products with the face of President Donald Trump and his alleged approval. The Mesothelioma Applied Research…
One of this year’s American Society for Clinical Oncology (ASCO) updates in mesothelioma included the release of the first results for the Phase 2 Study…
UPDATE: This study has been completed with the full analysis of all 54 patients. Click here for full results. Earlier this month, during the most…
A new article reviewing progress and advances that occurred in 2017 in the management of pleural mesothelioma was just published in the May 2018 issue…
In 2004, over 14 years ago (!), the FDA approved the first ever (and the last so far) mesothelioma treatment drug – Alimta (pemetrexed) in…
We are excited to report that Congress has funded the congressionally directed Department of Defense (DoD) funding for Fiscal Year 2018 (FY18) with $80 million…
The Mesothelioma Applied Research Foundation (Meso Foundation) commends the efforts of Sen. Jeff Merkley (D-OR) and the Asbestos Disease Awareness Organization (ADAO) for the introduction of…
IMPORTANT NEWS: The board of directors of the Meso Foundation is excited to announce that Mary Hesdorffer has been appointed executive director of the Foundation.…
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
